Three-year visual outcomes after brolucizumab in patients with neovascular age-related macular degeneration
The TAE regimen achieved better visual outcomes at 3 years. Residual SRF should be tolerated during the maintenance phase if the change of CFT was little compared to the previous image.
Authors
- Maiko Maruyama-Inoue (ORCID: https://orcid.org/0000-0002-8191-1329)
- Kazuaki Kadonosono (ORCID: https://orcid.org/0000-0003-3568-9111)
- Yasuhiro Kobayashi (ORCID: https://orcid.org/0000-0002-0903-3226)
- Tatsuya Inoue (ORCID: https://orcid.org/0000-0002-2481-0222)
- Yasuo Yanagi (ORCID: https://orcid.org/0000-0002-0362-7285)
Institutions
- Yokohama City University Medical Center (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- BMC Ophthalmology
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1186/s12886-025-04049-0
- Citations
- 1
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.71